Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVAS-an interesting california-based biotech company here -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (115)	3/5/2003 12:19:34 PM
From: nigel bates	Read Replies (1) \| Respond to of 126

MLNM might have made a more interesting fit ? The ceo could then use whatever settlement he arrived at on his contract to buy some DNDN in the open market. The MLNM stockprice would be a great deal less likely to take the dive that DNDN took on the announcement, so a deal closer to net cash could have been done.

To: keokalani'nui who wrote (115)	3/5/2003 5:58:03 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 126

<<Lampert 100% right IMO.>> Lampert is thinking only about his pocket. He played dirty early with CVAS and he will play dirty again. REW is a joke. He was living good life at SD and now it comes to the end. He is looking for exit (as Lampert is), and DNDN was probably best offer, if they did try to negotiate with other bios. MLNM is better choice, but MLNM is not in position to make major move at the moment. CVAS is afraid that NAPc2 will fail and they will have nothing than ~$50M cash to offer in few months. I do not know what is Provenge chance for success? Maybe better than NAPc2, maybe worse? Miljenko PS: CVAS chemistry is zero, protein biology may be bit better, but so far they did not generated anything.